A Device For Hypertension After All?
This article was originally published in Start Up
Despite industry-wide contraction last year after Medtronic's SYMPLICITY, many agree the trial was flawed, and some believe a hypertension device is just around the corner. A determined handful of medtech start-ups continue to pursue a device-based approach, most by reducing “fight-or-flight” outflow from the sympathetic nervous system.
You may also be interested in...
The big slice of the device industry, from large-cap firms to venture capitalists, with some stake in the renal denervation opportunity are trying to understand the new reality now that Medtronic’s pivotal Symplicity renal denervation device trial missed its endpoint.
Starting as the first company with a device therapy for resistant hypertension, CVRx was soon competing with the renal denervation avalanche, along with trying to survive the economic collapse and a failed trial. Fortunately, the company had gotten its funding when the getting was good.
Unlike other renal denervation technologies that apply destructive energy to the entire renal artery wall, , Ablative Solutions Inc. has developed a catheter-based approach that delivers ethanol directly to the nerves that encircle the renal artery, and destroys them without damaging the artery walls . The company is developing its Peregrine System for use in an outpatient setting to restore normal blood pressure in medication-resistant hypertensive patients.